Eli Lilly & Co. (LLY) reports Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. IONS
4. ACN
5. AZN
6. ROIV
7. AAPL
8. NVDA
9. USO
10. ORCL

Go back to Eli Lilly & Co. (LLY) reports Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1126.24 -23.12 (2.01%)
Previous Close $1149.36    52 Week High $88.16 
Open $1133.00    52 Week Low $67.88 
Day High $1134.53    P/E 260.70 
Day Low $1113.55    EPS $4.32 
Volume 1,286,620